An interventional study of Lidocaine HCl 1% in Catheterization, Central Venous, Pain, Procedural and Internal Jugular Vein Cannulation, sponsored by Kayseri City Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-07.
Sponsored by Kayseri City Hospital · Not applicable, Interventional, and Treatment
Among 11 studies testing lidocaine in Pain, Procedural — 1 open to participants now, 1 under way, none of them phase 3. Lidocaine · Pain, Procedural.
Among the 11 studies testing lidocaine in Pain, Procedural, this one is the 7th largest by enrollment, is one of 2 that started in 2025, is one of 2 with no phase, and was the 11th registered.
241 studies on the registry are indexed under Pain, Procedural; 64 are open to participants now.
This study's enrollment of 150 is above the median of 90 across 227 interventional studies indexed under Pain, Procedural.
Browse Pain, Procedural studies →1 of the 11 studies testing lidocaine in Pain, Procedural is open now.
Lidocaine: first FDA approval 1948 (XYLOCAINE), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 29 Pain, Procedural studies recruiting now, 13 (45%) set no upper age limit and 14 (48%) stop at 75 or younger; 14 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →11 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2025.
Median enrollment 180 across the 11 interventional studies. Of the 8 that completed or were terminated, 1 (13%) have results posted.
4 of 11 have an industry lead sponsor. The 9 most frequent:
Kayseri City Hospital is the lead sponsor of 49 studies on the registry; 15 are open to participants now.
Kayseri City Hospital has 1 study filed under Pain, Procedural — fewer than ten, so there is no comparison to draw.
1 of the studies testing lidocaine in Pain, Procedural that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07792668Balikesir UniversityPain Control During Hysterosalpingography: A Three-Arm Randomized Trial | 2027-06-01 |
Among the 11 studies testing lidocaine in Pain, Procedural, from their registry updates:
Internal jugular vein (IJV) catheterization is a common invasive procedure performed under ultrasound (USG) guidance. Providing effective analgesia during the procedure is essential for patient comfort. This prospective, randomized controlled study aims to compare the clinical efficacy, onset time, required local anesthetic volume, and hemodynamic stability between ultrasound-guided local infiltration anesthesia (LIA) and ultrasound-guided superficial cervical plexus block (SCPB) using different volumes (2 mL, 5 mL, and 10 mL of 1% lidocaine) in patients undergoing IJV catheterization.
Central venous catheterization (CVC) is a widely used invasive procedure in critically ill and high-risk surgical patients for fluid resuscitation, hemodynamic monitoring, continuous infusion of vasoactive or venosclerotic drugs, and hemodialysis/hemofiltration. Among available vascular access sites, internal jugular vein (IJV) cannulation is the most commonly preferred route. However, awake patients undergoing IJV catheterization often experience significant pain and distress, which may negatively impact hemodynamic stability, patient comfort, and procedural success.
Although local infiltration anesthesia (LIA) is traditionally used to provide analgesia during IJV catheterization, it frequently falls short of providing optimal pain control. Ultrasound-guided regional anesthesia techniques, such as superficial cervical plexus block (SCPB), have emerged as effective alternatives for procedures involving the anterolateral neck region.
While both LIA and SCPB are utilized in clinical practice, there is a lack of prospective randomized literature directly comparing different local anesthetic volumes, onset times, and overall clinical efficacy between these two approaches. This prospective, randomized controlled trial aims to evaluate and compare ultrasound-guided LIA and SCPB in terms of anesthetic efficacy, onset time, required local anesthetic volume, and hemodynamic stability in patients undergoing IJV catheterization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients aged between 18 and 80 years
(ASA) physical status I-III
Glasgow Coma Scale (GCS) score between 13 and 15
Patients scheduled for elective or semi-elective ultrasound-guided internal jugular vein catheterization
Patients who are literate, capable of effective communication, and provide written
Exclusion Criteria:
Age \< 18 years or > 80 years
IV or higher
Internal jugular vein catheterization performed under general anesthesia
Internal jugular vein catheterization performed under emergency conditions
Distorted head and neck anatomy preventing adequate ultrasound visualization for the block
Arterial puncture on the first needle insertion attempt
Illiterate patients or patients unable to establish effective communication to evaluate pain scores
Known allergy or to local anesthetics
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
10 mL of 1% lidocaine hydrochloride is injected subcutaneously over the sternocleidomastoid muscle at the C6 level for local infiltration prior to internal jugular vein catheterization (n=75).
Drug: Lidocaine HCl 1%
Ultrasound-guided superficial cervical plexus block administered beneath the sternocleidomastoid muscle at the C6 level using 2 mL of 1% lidocaine hydrochloride (n=25).
Drug: Lidocaine HCl 1%
Ultrasound-guided superficial cervical plexus block administered beneath the sternocleidomastoid muscle at the C6 level using 5 mL of 1% lidocaine hydrochloride (n=25).
Drug: Lidocaine HCl 1%
Ultrasound-guided superficial cervical plexus block administered beneath the sternocleidomastoid muscle at the C6 level using 10 mL of 1% lidocaine hydrochloride (n=25).
Drug: Lidocaine HCl 1%
Administration of 1% lidocaine hydrochloride either via ultrasound-guided superficial cervical plexus block (at 2 mL, 5 mL, or 10 mL volumes) or via subcutaneous local infiltration (10 mL) prior to internal jugular vein catheterization.
Also known as: LİDON %2 (diluted %1)
Time to Effective Block Onset Across Different Local Anesthetic Volumes
Time elapsed (in seconds) from injection completion until effective analgesia is achieved (defined as an NRS score ≤ 2 via pin-prick test every 5 seconds), evaluating whether lower volumes of SCPB (2 mL and 5 mL) achieve effective block onset in a comparable timeframe to higher volume SCPB (10 mL) and standard LIA (10 mL).
Time frame: Evaluated every 5 seconds, up to 5 minutes post-injection.
Time to Effective Block Onset Across Different Local Anesthetic Volumes
Time elapsed (in seconds) from injection completion until effective analgesia is achieved (defined as an NRS score ≤ 2 via pin-prick test every 5 seconds), evaluating whether lower volumes of SCPB (2 mL and 5 mL) achieve effective block onset in a comparable timeframe to higher volume SCPB (10 mL) and standard LIA (10 mL).
Time frame: Evaluated every 5 seconds, up to 5 minutes post-injection
Pain Intensity Across Procedural Stages (NRS Scores)
Evaluation of pain intensity using the Numerical Rating Scale (NRS, 0 = no pain to 10 = worst pain) to compare whether low-volume SCPB provides comparable pain control to high-volume SCPB and LIA across different procedural steps.
Time frame: At baseline, during infiltration/block injection, during initial needle insertion, and during catheter placement.
Plan to share: No — Individual participant data will not be shared to protect patient confidentiality and due to lack of a dedicated data repository protocol.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lidocaine
Kayseri City Hospital